­Sent by email to: XXXXXXXXXXXXXXXXXXXXXXXXX

XXXX XXXXXXXXXXXXX,

British Society for Heart Failure,

33 Cavendish Square,

London

W1G 0PW

29 January 2021

Dear XX XXXXXXXXXXXXX

**Re: Final Appraisal Determination – Heart failure (reduced ejection fraction) - dapagliflozin [ID1656]**

Thank you for your reply to my letter of 14 January 2021.

I stated in my initial scrutiny letter that I was not minded to refer the British Society for Heart Failure’s appeal to an appeal panel for further consideration, and I invited the BSHF to comment on the letter in order to elaborate or clarify any of the points raised before I made my final decision. Based on your response, I have taken the decision that NICE will not be conducting an appeal hearing. Therefore, the final appraisal document will return to the technology appraisal team to take forward.

Many thanks

Yours sincerely

XXXXXXXXXX

Tim Irish

Vice Chair

National Institute for Health and Care Excellence